A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenPrevention and treatment of bone fragility in cancer patientBone anabolics in osteoporosis: Actuality and perspectivesIdentification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meetingStrontium ranelate improves delayed healing of osteolytic lesions of the jaw in a man with chronic osteomyelitis. Case reportMaintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAXWhen the FRAX(®) test is applied to controlled clinical trials.Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.FRAX and the effect of teriparatide on vertebral and non-vertebral fractureNew horizons in treatment of osteoporosis.Current options for the management of postmenopausal osteoporosis.Goal-directed treatment of osteoporosis in Europe.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.FRAX and fracture prediction without bone mineral density.Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures.Fracture risk assessment without bone density measurement in routine clinical practice.The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.Improving adherence to and persistence with oral therapy of osteoporosis.Does osteoporosis therapy invalidate FRAX for fracture prediction?Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.Comparable effects of alendronate and strontium ranelate on femur in ovariectomized rats.An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FDenosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.Strontium: friend or foe of bone formation?Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.The distribution of FRAX(®)-based probabilities in women from Japan.Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Rats.Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.Pharmacological Therapy of Osteoporosis: A Systematic Current Review of Literature.Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study.
P2860
Q24612411-148F9635-1CA5-431B-B0B8-B3DCE469F3B2Q26775765-1BC38C94-690A-4C72-9AD8-FAAF03ABB6C7Q27691122-B03C9BD1-4A3A-414E-AE6C-E0A0815E3ACCQ30234621-45F134F7-1C12-441E-A91D-0B71259676F3Q33781635-3F868E94-5E43-46AF-86E4-029582DBDBDEQ34029575-2F122B37-397C-4525-8845-A1DD863F8CD5Q35941201-11B92540-D94D-4227-B47B-6C39A74EBE76Q36505613-4F384091-9202-4AC7-AC7C-FB7F5B6B947EQ36997684-269F1058-A9FC-4FF7-BD4E-25E77139820BQ37021082-4AA84340-9F14-41E7-9023-9DF7D61CD057Q37630995-79BBF83E-7922-4352-A4FD-02E7DFF76DDFQ37931985-8FBC90EE-DA5D-44E8-9323-BC47D57135EBQ38246948-5EAAE27E-6DC9-435D-82CE-BD8857534020Q38611601-EC7CB981-264A-4089-AB71-F509B41EDB38Q38613173-6AE1E454-CF85-4E49-943D-E4D2DBE25402Q39361838-D5BC105B-A778-4463-ADAD-CBD42D94F887Q39716469-17AA309D-E857-4265-9A18-2EFDAF282147Q40214077-A11BF1E0-CB72-4D1D-9B78-2C063A0A535FQ41529661-6B1D913B-B39C-4178-AC5C-5796E47B805BQ43477917-004258DD-B813-4BEB-814C-3707976FA4FDQ43876049-C69CA3D9-9754-45EB-B303-075EC9B3377EQ44063452-17D3853E-F504-4B08-82BD-FB69F7E7EA90Q44655591-44DCCBB0-AEFF-495B-B8CE-66D1FFA495FFQ44662093-BD6AF615-416E-4E12-A052-2261E95128F4Q44907080-152A4CAB-A4C7-4A46-A705-F0E667EB2FFBQ46281373-B4E16040-825F-4730-9CAE-9EBCD7B45AA5Q47117629-65D3F14C-7DBB-4454-9D5C-0D4F812143B7Q47237107-F1E17F68-CA32-4B71-ABBE-3F073DAF1D49Q47291611-01CEC734-FBB8-40E7-8B36-9E07CDF5BAE9Q48154405-7594F0FB-1531-4D6B-AA11-063B9D3447B0Q49165503-C98BEEA4-A13F-4F01-80E1-150CAC312FBDQ51747695-D51F11FD-CFDB-46CA-8A78-B198BE33B0F0
P2860
A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A meta-analysis of the effect ...... and the interaction with FRAX
@nl
A meta-analysis of the effect ...... the interaction with FRAX(®).
@ast
A meta-analysis of the effect ...... the interaction with FRAX(®).
@en
type
label
A meta-analysis of the effect ...... and the interaction with FRAX
@nl
A meta-analysis of the effect ...... the interaction with FRAX(®).
@ast
A meta-analysis of the effect ...... the interaction with FRAX(®).
@en
prefLabel
A meta-analysis of the effect ...... and the interaction with FRAX
@nl
A meta-analysis of the effect ...... the interaction with FRAX(®).
@ast
A meta-analysis of the effect ...... the interaction with FRAX(®).
@en
P2093
P2860
P1476
A meta-analysis of the effect ...... the interaction with FRAX(®).
@en
P2093
E V McCloskey
H Johansson
P2860
P2888
P304
P356
10.1007/S00198-010-1474-0
P407
P577
2011-02-02T00:00:00Z
P6179
1044446276